

Overall survival in patients with BRAF-mutant melanoma treated with binimetinib versus vemurafenib or encorafenib (COLUMBIA), a randomised, phase 3 trial

Lancet Oncology, The
19, 1315-1327

DOI: [10.1016/s1470-2045\(18\)30497-2](https://doi.org/10.1016/s1470-2045(18)30497-2)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 743-771.		0
4	Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors. JAMA Network Open, 2019, 2, e198890.	2.8	96
5	Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. Cancers, 2019, 11, 1176.	1.7	20
7	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European Journal of Cancer, 2019, 119, 97-106.	1.3	75
8	Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection. Frontiers in Medicine, 2019, 6, 140.	1.2	9
10	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer, 2019, 19, 665.	1.1	42
11	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Current Oncology Reports, 2019, 21, 76.	1.8	18
12	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist, 2019, 24, e1197-e1211.	1.9	15
13	Targeted therapy for malignant melanoma. Current Opinion in Pharmacology, 2019, 46, 116-121.	1.7	19
14	A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein. Molecular Therapy - Nucleic Acids, 2019, 18, 727-738.	2.3	27
15	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 2019, 123, 58-71.	1.3	45
16	Novel Targets for the Treatment of Melanoma. Current Oncology Reports, 2019, 21, 97.	1.8	15
17	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers, 2019, 11, 1642.	1.7	47
18	The adjuvant treatment revolution for high-risk melanoma patients. Seminars in Cancer Biology, 2019, 59, 283-289.	4.3	40
19	BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers, 2019, 11, 1262.	1.7	99
20	Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. Cancers, 2019, 11, 1342.	1.7	22
21	Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression. International Journal of Molecular Sciences, 2019, 20, 4484.	1.8	18
22	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	13.9	918

#	ARTICLE	IF	CITATIONS
23	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
24	Defining subpopulations of differential drug response to reveal novel target populations. <i>Npj Systems Biology and Applications</i> , 2019, 5, 36.	1.4	18
25	Targeted Therapy and Immunotherapy for Melanoma in Japan. <i>Current Treatment Options in Oncology</i> , 2019, 20, 7.	1.3	79
26	Early-phase clinical drug development of novel agents: a changing paradigm. <i>Annals of Oncology</i> , 2019, 30, 1033-1037.	0.6	5
27	Management of metastatic cutaneous melanoma: updates in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985166.	1.4	29
28	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. <i>ESMO Open</i> , 2019, 4, e000491.	2.0	140
29	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 990.	2.2	86
30	Reinduktion zielgerichteter Therapie beim metastasierten Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 483-487.	0.4	1
31	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	13.9	909
32	Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2019, 20, 49.	1.3	6
33	Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 955-972.	2.5	50
34	Variant classification in precision oncology. <i>International Journal of Cancer</i> , 2019, 145, 2996-3010.	2.3	76
35	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 1-29.		0
36	Encorafenib + binimetinib: a profile of their combined use in treating BRAF-mutated unresectable or metastatic melanoma. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 151-159.	0.3	0
37	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	1.6	6
38	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
39	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
40	Evaluation of cutaneous adverse events of encorafenib and binimetinib: COMMENT on article by Graf etÂal .. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 630-631.	1.3	0

#	ARTICLE	IF	CITATIONS
41	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	0.8	188
42	Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 111, 8-11.	1.3	6
43	Rechallenge of targeted therapy in metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 483-486.	0.4	13
44	Management of V600E and V600K <i>BRAF</i> -Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 81.	1.3	28
45	Melanoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 543-553.	0.7	1
46	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	0.6	16
47	Systemic therapies for unresectable locoregional melanoma: a significant area of need. <i>Melanoma Management</i> , 2019, 6, MMT25.	0.1	6
48	Clinical Application of Next-Generation Sequencing-Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 937-944.	1.9	14
49	Overcoming the resistance to <i>BRAF</i> inhibitor by the double <i>BRAF</i> and <i>MEK</i> inhibitions in advanced melanoma: a case report. <i>Anti-Cancer Drugs</i> , 2019, 30, 1052-1054.	0.7	3
50	<i>BRAF</i> kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 143-148.	1.9	16
51	Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with <i>BRAF</i> mutations. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 259-266.	1.3	44
52	Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. <i>Acta Oncologica</i> , 2020, 59, 310-314.	0.8	5
53	Network indirect comparison of 3 <i>BRAF</i> + <i>MEK</i> inhibitors for the treatment of advanced <i>BRAF</i> mutated melanoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 900-907.	1.2	8
54	Principles of Targeted Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 175-188.	0.5	40
55	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. <i>Cancer</i> , 2020, 126, 523-530.	2.0	43
56	Image Guided Dermatologic Treatments. , 2020, , .		4
57	Synthetic lethality as an engine for cancer drug target discovery. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 23-38.	21.5	295
58	Mitogen-activated protein kinase dependency in <i>BRAF</i> / <i>RAS</i> wild-type melanoma: A rationale for combination inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 345-357.	1.5	2

#	ARTICLE	IF	CITATIONS
59	The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review. <i>International Journal of Cancer</i> , 2020, 146, 1479-1489.	2.3	20
60	Brain malignancies: Glioblastoma and brain metastases. <i>Seminars in Cancer Biology</i> , 2020, 60, 262-273.	4.3	208
61	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 367-383.	1.0	21
62	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600E mutant melanoma. <i>European Journal of Cancer</i> , 2020, 126, 33-44.	1.3	130
63	Novedades terapéuticas en dermatología. <i>Piel</i> , 2020, 35, 4-9.	0.0	0
64	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma. <i>Translational Oncology</i> , 2020, 13, 275-286.	1.7	13
65	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. <i>Current Opinion in Oncology</i> , 2020, 32, 79-84.	1.1	25
66	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 53-62.	1.1	6
67	Nongenetic Mechanisms of Drug Resistance in Melanoma. <i>Annual Review of Cancer Biology</i> , 2020, 4, 315-330.	2.3	18
68	Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020, 32, 85-90.	1.1	8
69	Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. <i>Cancers</i> , 2020, 12, 2801.	1.7	73
70	Real-world treatment practice in patients with advanced melanoma. <i>Wspolczesna Onkologia</i> , 2020, 24, 118-124.	0.7	6
71	Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma. <i>Uppsala Journal of Medical Sciences</i> , 2020, 125, 325-329.	0.4	8
73	Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases. <i>Melanoma Research</i> , 2020, 30, 519-523.	0.6	4
74	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	0.6	132
75	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	1.3	11
76	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. <i>European Journal of Cancer</i> , 2020, 138, 68-76.	1.3	10
77	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2020, 26, 1564-1568.	15.2	71

#	ARTICLE	IF	CITATIONS
78	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> V600E/K-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	3.2	23
79	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. <i>Cancer Immunology Research</i> , 2020, 8, 1114-1121.	1.6	9
80	Rapid BRAF Mutation Testing in Pigmented Melanomas. <i>American Journal of Dermatopathology</i> , 2020, 42, 343-348.	0.3	7
81	Targeted and immunotherapies in <i>BRAF</i> mutant melanoma: where we stand and what to expect. <i>British Journal of Dermatology</i> , 2021, 185, 253-262.	1.4	20
82	A Blue Light-Inducible CRISPR-Cas9 System for Inhibiting Progression of Melanoma Cells. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 606593.	1.6	13
83	Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. <i>Cancers</i> , 2020, 12, 3456.	1.7	12
84	CDK4/6 and MAPK Crosstalk as Opportunity for Cancer Treatment. <i>Pharmaceuticals</i> , 2020, 13, 418.	1.7	28
85	The Role of BRAF in Metastatic Colorectal Carcinoma—Past, Present, and Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9001.	1.8	8
86	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
87	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59
88	Hydroxynaphthalenecarboxamides and substituted piperazinylopropanediols, two new series of BRAF inhibitors. A theoretical and experimental study. <i>Bioorganic Chemistry</i> , 2020, 103, 104145.	2.0	8
89	Preclinical discovery and clinical development of encorafenib for the treatment of melanoma. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1373-1380.	2.5	7
90	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. <i>Cell Reports</i> , 2020, 31, 107764.	2.9	69
91	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2430.	1.0	10
92	Clinical Development of BRAF plus MEK Inhibitor Combinations. <i>Trends in Cancer</i> , 2020, 6, 797-810.	3.8	169
93	Advances in the Systemic Treatment of Melanoma Brain Metastases. , 2020, , .		0
94	Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. <i>Cancers</i> , 2020, 12, 3004.	1.7	3
95	Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib. <i>European Journal of Cancer</i> , 2020, 139, 37-40.	1.3	2

#	ARTICLE	IF	CITATIONS
96	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	6.9	226
97	Treatment of Advanced Melanoma: Past, Present and Future. <i>Life</i> , 2020, 10, 208.	1.1	18
98	Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1229-1236.	1.0	3
99	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	0.6	14
101	Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. <i>Melanoma Research</i> , 2020, 30, 477-483.	0.6	5
103	B-Raf-Mutated Melanoma. , 2020, , .		0
104	Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9730.	1.8	15
105	Censored patients in Kaplan–Meier plots of cancer drugs: An empirical analysis of data sharing. <i>European Journal of Cancer</i> , 2020, 141, 152-161.	1.3	13
106	Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15883-15905.	2.9	21
107	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 571135.	1.3	2
108	miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma. <i>Neoplasia</i> , 2020, 22, 789-799.	2.3	9
110	Surgery for Unresectable Stage IIIc and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
111	Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer. <i>Facial Plastic Surgery</i> , 2020, 36, 200-210.	0.5	7
112	BRAF mutation and its inhibitors in sarcoma treatment. <i>Cancer Medicine</i> , 2020, 9, 4881-4896.	1.3	26
113	MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 746-753.	0.9	4
114	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
115	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients – A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2188-2200.	0.7	4
116	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	5.7	23

#	ARTICLE	IF	CITATIONS
117	Neoadjuvant Therapy for Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 445-453.	0.6	2
118	Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. <i>Kidney Medicine</i> , 2020, 2, 373-375.	1.0	5
119	Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant BRAF ^{V600E} Melanoma. <i>Cancers</i> , 2020, 12, 1500.	1.7	9
120	Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. <i>Targeted Oncology</i> , 2020, 15, 407-410.	1.7	17
121	<p>Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors " Results of a Prospective Biomarker Study</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5017-5032.	1.0	9
122	Pre-clinical modeling of cutaneous melanoma. <i>Nature Communications</i> , 2020, 11, 2858.	5.8	133
123	Targeted Therapy for Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 409-434.	0.8	11
124	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 653-664.	1.5	7
125	Combination of PD‑1 inhibitor and targeted therapy in advanced <i>BRAF</i> V600E‑mutant melanoma with symptomatic brain metastases: a report of five cases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 901-904.	0.4	1
126	Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 486.	1.8	42
127	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	1.3	84
128	Targeting complex, adaptive responses in melanoma therapy. <i>Cancer Treatment Reviews</i> , 2020, 86, 101997.	3.4	8
129	The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. <i>Scientific Reports</i> , 2020, 10, 4940.	1.6	12
130	The discovery and development of binimetinib for the treatment of melanoma. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 745-754.	2.5	25
131	Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 493-504.	3.3	30
132	BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases. <i>Neoplasia</i> , 2020, 22, 376-389.	2.3	14
133	Adjuvant Therapy for Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 455-465.	0.6	1
134	Molecular therapeutic targets in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 647-661.	1.1	46

#	ARTICLE	IF	CITATIONS
135	A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 1056.	1.3	5
136	BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. <i>Cancers</i> , 2020, 12, 1823.	1.7	82
137	Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. <i>Targeted Oncology</i> , 2020, 15, 531-540.	1.7	12
138	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	1.4	31
139	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 20-31.	1.5	19
140	Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. <i>Cancer Treatment Reviews</i> , 2020, 88, 102060.	3.4	27
141	Current Advances in the Treatment of BRAF-Mutant Melanoma. <i>Cancers</i> , 2020, 12, 482.	1.7	112
142	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> , 2020, 12, 512.	1.7	15
143	An overview of binimetinib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 747-754.	0.9	8
144	RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. <i>Neuro-Oncology Practice</i> , 2020, 7, 369-375.	1.0	2
145	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 875-885.	3.0	20
146	Secondary histiocytic sarcoma with BRAF ^{V600E} mutation after Tâ€cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28200.	0.8	12
147	<i>GNAQ</i> and <i>GNA11</i> mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. <i>British Journal of Dermatology</i> , 2020, 183, 928-939.	1.4	24
148	Encorafenib, binimetinib and cetuximab combined therapy for patients with <i>BRAFV600E</i> mutant metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 161-173.	1.1	9
149	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 417.	1.8	32
150	Nanosystems for Improved Targeted Therapies in Melanoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 318.	1.0	30
151	Autophagy regulation as a promising approach for improving cancer immunotherapy. <i>Cancer Letters</i> , 2020, 475, 34-42.	3.2	32
152	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020, 9, 7.	2.0	11

#	ARTICLE	IF	CITATIONS
154	Toward a More Precise Future for Oncology. <i>Cancer Cell</i> , 2020, 37, 431-442.	7.7	21
155	Metastatic Melanoma Patientâ€™Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 3803-3818.	3.2	21
156	Improvements in Clinical Outcomes for <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4435-4441.	3.2	17
157	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	0.8	190
158	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. <i>Cancer Treatment Reviews</i> , 2020, 86, 101998.	3.4	25
159	Emerging strategies to treat rare and intractable subtypes of melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 44-58.	1.5	22
160	Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a realâ€™world setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 105-115.	1.3	9
161	miR-942-5p promotes the proliferation and invasion of human melanoma cells by targeting <i>DKK3</i> . <i>Journal of Receptor and Signal Transduction Research</i> , 2021, 41, 180-187.	1.3	17
163	Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus. <i>Histopathology</i> , 2021, 78, 240-251.	1.6	9
164	First-line immunotherapy versus targeted therapy in patients with <i>BRAF</i> -mutant advanced melanoma: a real-world analysis. <i>Future Oncology</i> , 2021, 17, 689-699.	1.1	21
165	Prevalence of class III <i>BRAF</i> mutations among 114,662 cancer patients in a large genomic database. <i>Experimental Biology and Medicine</i> , 2021, 246, 31-39.	1.1	36
166	Patient preferences for treatment of advanced melanoma: impact of comorbidities. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 58-70.	0.4	7
167	Current Management of Melanoma. <i>Updates in Surgery Series</i> , 2021, , .	0.0	0
168	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2021, 16, 37-46.	1.7	5
169	BH3 mimetics potentiate pro-apoptotic activity of encorafenib in <i>BRAF</i> V600E melanoma cells. <i>Cancer Letters</i> , 2021, 499, 122-136.	3.2	13
170	Case series of <i>BRAF</i> -mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. <i>Journal of Dermatology</i> , 2021, 48, 397-400.	0.6	7
171	Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 111-128.	0.9	5
172	Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelinesâ€™. <i>Annals of Oncology</i> , 2021, 32, 157-170.	0.6	65

#	ARTICLE	IF	CITATIONS
173	Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma. <i>Dermatologic Therapy</i> , 2021, 34, e14544.	0.8	1
174	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. <i>Targeted Oncology</i> , 2021, 16, 47-57.	1.7	8
175	Biology of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 29-56.	0.9	40
176	Systematic review of BRAF/MEK inhibitorsâ€induced Severe Cutaneous Adverse Reactions (SCARs). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 607-614.	1.3	26
177	Alternative use of BRAF inhibitors in patients with metastatic melanoma unable to swallow pills. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 996-999.	0.5	2
178	Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129736.	1.1	38
179	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
182	Dabrafenib and Trametinib. , 2021, , 131-147.		0
183	New Therapies in Advanced Cutaneous Malignancies: Conclusions. , 2021, , 441-448.		1
184	Drug resistance in targeted cancer therapies with RAF inhibitors. , 2021, 4, 665-683.		9
185	Cell Proliferation Is Strongly Associated with the Treatment Conditions of an ER Stress Inducer New Anti-Melanoma Drug in Melanoma Cell Lines. <i>Biomedicines</i> , 2021, 9, 96.	1.4	5
186	Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2021, 112, 142-152.	0.2	2
188	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600Eâ€Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-284.	0.8	254
189	Defining and Targeting BRAF Mutations in Solid Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 30.	1.3	25
190	Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 364-370.	0.6	3
191	Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma. <i>Cancers</i> , 2021, 13, 1421.	1.7	5
192	BRAF Gene and Melanoma: Back to the Future. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3474.	1.8	40
193	Circulating tumour DNA in patients with melanoma receiving targeted therapy. <i>Lancet Oncology</i> , The, 2021, 22, 291-293.	5.1	0

#	ARTICLE	IF	CITATIONS
194	Recent advancements in melanoma management. <i>Internal Medicine Journal</i> , 2021, 51, 327-333.	0.5	4
195	Inhibition of FGF α -FGFR and VEGF α -VEGFR signalling in cancer treatment. <i>Cell Proliferation</i> , 2021, 54, e13009.	2.4	76
196	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	3.3	18
197	First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?. <i>JMIR Cancer</i> , 2021, 7, e29912.	0.9	4
198	A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma \sim . <i>ESMO Open</i> , 2021, 6, 100050.	2.0	14
199	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data \sim . <i>Annals of Oncology</i> , 2021, 32, 542-551.	0.6	13
200	Impact of novel systemic therapies on the first \sim year costs of care for melanoma among Medicare beneficiaries. <i>Cancer</i> , 2021, 127, 2926-2933.	2.0	7
202	Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. <i>PLoS ONE</i> , 2021, 16, e0252314.	1.1	3
204	Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 393-396.	0.6	2
205	Recent Advances in Synthesis and Biological Assessment of Quinoline \sim Oxygen Heterocycle Hybrids. <i>ChemistrySelect</i> , 2021, 6, 5148-5165.	0.7	11
206	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross \sim sectional and longitudinal analysis using two large national registries. <i>Cancer Medicine</i> , 2021, 10, 3862-3872.	1.3	17
207	Systemic Therapy for Head and Neck Skin Cancers. <i>Face</i> , 2021, 2, 121-130.	0.1	0
208	The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 290-297.	0.6	2
209	Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199.	1.7	8
210	Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1317-1324.e1.	0.3	9
211	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
212	Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3709-3719.	1.0	24
214	The role of immunotherapy and molecular \sim targeted therapy in the treatment of melanoma (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	14

#	ARTICLE	IF	CITATIONS
215	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
216	Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 55.	1.3	4
217	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 670726.	1.3	26
218	Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600 melanoma patients. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 32-38.	0.5	4
219	A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 21-29.	0.9	8
220	Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 5699-5709.	0.9	6
221	Advances in the discovery and development of melanoma drug therapies. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1319-1347.	2.5	9
222	Recognition, Staging, and Management of Melanoma. <i>Medical Clinics of North America</i> , 2021, 105, 643-661.	1.1	4
223	A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. <i>Journal of Thoracic Disease</i> , 2021, 13, 4054-4062.	0.6	9
224	New systemic therapies for cutaneous melanoma: why, who and what. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 344-355.	0.1	2
225	Treatment of Advanced Metastatic Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021164S.	0.5	10
226	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	1.3	7
227	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.4	9
228	Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1297-1305.	0.4	6
229	Biomarkers in metastatic melanoma of the skin: can we more accurately choose the tactics of treating our patients?. <i>Meditinskiy Sovet</i> , 2021, , 48-63.	0.1	2
230	Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 107-119.	1.0	2
231	Hypertension Induced by Combination Therapy of Cancer: A Systematic Review and Meta-Analysis of Global Clinical Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 712995.	1.6	5
232	Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 349-360.	0.4	0

#	ARTICLE	IF	CITATIONS
233	Gibt es eine Überbehandlung von Melanompatienten am Ende ihres Lebens? Ergebnisse einer multizentrischen Studie an 193 Melanompatienten. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1297-1306.	0.4	0
234	Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. Current Oncology, 2021, 28, 3537-3553.	0.9	5
235	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. Annales De Dermatologie Et De Venereologie, 2021, 148, 145-155.	0.5	4
236	Immune checkpoint inhibitors in melanoma. Lancet, The, 2021, 398, 1002-1014.	6.3	462
237	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. Cancers, 2021, 13, 4780.	1.7	8
238	Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India. Frontiers in Oncology, 2021, 11, 710585.	1.3	7
239	Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor. British Journal of Dermatology, 2021, , .	1.4	0
240	Dermatologic adverse events associated with targeted therapies for melanoma. Expert Opinion on Drug Safety, 2022, 21, 385-395.	1.0	0
241	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. Expert Review of Precision Medicine and Drug Development, 2021, 6, 19-29.	0.4	3
242	Immunotherapy for Melanoma. Advances in Experimental Medicine and Biology, 2020, 1244, 51-68.	0.8	41
243	Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models. Neuro-Oncology, 2021, 23, 770-782.	0.6	18
244	Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass. Melanoma Research, 2020, 30, 625-627.	0.6	5
245	Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma. Journal of Dermatology, 2021, 48, 707-709.	0.6	3
246	Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report. Pteridines, 2020, 31, 151-157.	0.5	1
247	New drug: Binimetinib plus encorafenib for metastatic melanoma. Australian Prescriber, 2019, 42, 168-168.	0.5	2
248	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. Deutsches ̈rzteblatt International, 2019, 116, 497-504.	0.6	15
249	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Frontiers in Oncology, 2019, 9, 263.	1.3	62
250	Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer. Oncology Letters, 2020, 19, 2685-2694.	0.8	6

#	ARTICLE	IF	CITATIONS
251	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	2.3	326
252	Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1150-1155.	2.3	5
253	Cutaneous Melanoma and Other Skin Cancers. UNIPA Springer Series, 2021, , 979-1007.	0.1	0
254	Evaluating Optimal Treatment for Melanoma: A Network Meta-Analysis. Chinese Journal of Plastic and Reconstructive Surgery, 2021, 3, 27-31.	0.1	0
255	Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis. Current Oncology, 2021, 28, 3978-3986.	0.9	7
256	Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. Annals of Oncology, 2021, , .	0.6	5
257	PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma. Molecular Imaging and Biology, 2022, 24, 425-433.	1.3	3
258	Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. Acta Oncologica, 2022, 61, 45-51.	0.8	3
259	BRAF-mutant Melanoma – The COLUMBUS Trial. European Oncology and Haematology, 2018, 14, 78.	0.0	0
261	Neue Arzneimittel 2018. , 2019, , 61-175.		1
262	We shall overcome (drug resistance) some day. Oncotarget, 2019, 10, 84-85.	0.8	1
263	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
264	Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.		0
265	Skin Care During and After Radiotherapy and Anticancer Treatment. , 2020, , 1-16.		0
266	Tumors: Melanoma. , 2020, , 1-11.		0
267	Prevalence of <i>BRAF</i> V600 in glioma and use of <i>BRAF</i> Inhibitors in patients with <i>BRAF</i> V600 mutation-positive glioma: systematic review. Neuro-Oncology, 2022, 24, 528-540.	0.6	26
268	MAPK blockade, toxicities, pathogenesis and management. Current Opinion in Oncology, 2021, 33, 139-145.	1.1	3
269	Bilateral Serous Retinal Detachment Associated with a Mitogen-activated Protein Kinase Kinase Inhibitor in a Patient with <i>BRAF</i> -mutant Colorectal Cancer. Internal Medicine, 2022, 61, 1707-1712.	0.3	2

#	ARTICLE	IF	CITATIONS
270	Glimmers of Hopeâ€”New Strategies for Overcoming Treatment Resistance in Patients with <i>BRAF</i> V600E-mutated Metastatic Colorectal Cancer. <i>Oncology & Hematology Review</i> , 2020, 16, 31.	0.2	1
271	Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00174.	0.6	0
272	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
273	Context Mattersâ€”Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760705.	1.8	3
275	Systemic Treatment in Advanced Melanoma. <i>Updates in Surgery Series</i> , 2021, , 167-174.	0.0	0
276	Clinicopathologic features and prognosis of epithelioid glioblastoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 1529-1539.	0.5	1
277	Tumors: Melanoma. , 2021, , 5260-5270.		0
278	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 771335.	1.3	15
279	Identification of a novel tumour microenvironmentâ€”based prognostic biomarker in skin cutaneous melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10990-11001.	1.6	8
280	Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor. <i>Clinical Cancer Research</i> , 2022, 28, 770-780.	3.2	10
281	Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. <i>Nature Communications</i> , 2021, 12, 7008.	5.8	22
282	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111.	0.8	7
283	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. <i>Oncologist</i> , 2022, 27, e463-e470.	1.9	7
284	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 17-25.	1.1	7
285	LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer. <i>Cancer Letters</i> , 2022, 529, 37-52.	3.2	18
286	Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights. <i>Current Opinion in Oncology</i> , 2022, 34, 115-122.	1.1	4
287	Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. <i>Npj Systems Biology and Applications</i> , 2022, 8, 2.	1.4	0
288	Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 114040.	2.6	5

#	ARTICLE	IF	CITATIONS
289	Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 284.	1.4	2
290	Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1837-1849.	2.0	2
292	Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells. <i>Frontiers in Oncology</i> , 2022, 12, 794216.	1.3	10
293	Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management. <i>Current Oncology Reports</i> , 2022, 24, 265.	1.8	2
294	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	3.4	21
295	The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. <i>Cancers</i> , 2022, 14, 777.	1.7	3
296	Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 828.	1.0	10
297	Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 413-418.	0.4	7
298	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
301	Encorafenib plus binimetinib in patients with <i>BRAF</i> ^{V600} -mutant non-small cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	1.1	9
302	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3002-3010.	3.2	18
303	The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response. <i>PLoS Computational Biology</i> , 2022, 18, e1009919.	1.5	4
304	Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. <i>Cell Reports</i> , 2022, 39, 110634.	2.9	10
305	Characterization of the treatment-naïve immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
306	Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103646.	2.0	3
307	A protocol for phase II study investigating the safety and efficacy of TM5614 in combination with nivolumab in the treatment of unresectable malignant melanoma. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 2, e0197.	0.0	0
308	Can Systems Biology Advance Clinical Precision Oncology?. <i>Cancers</i> , 2021, 13, 6312.	1.7	10
332	Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors. <i>European Journal of Dermatology</i> , 2019, 29, 107-108.	0.3	1

#	ARTICLE	IF	CITATIONS
334	The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 864302.	1.6	6
335	A Novel Risk Model Based on Autophagy-Related LncRNAs Predicts Prognosis and Indicates Immune Infiltration Landscape of Patients With Cutaneous Melanoma. <i>Frontiers in Genetics</i> , 2022, 13, 885391.	1.1	7
336	Evolving Treatment Approaches to Mucosal Melanoma. <i>Current Oncology Reports</i> , 2022, 24, 1261-1271.	1.8	7
337	Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 4618-4628.	3.2	37
338	Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 523-545.	3.3	2
339	Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy. <i>Case Reports in Oncology</i> , 0, , 469-472.	0.3	1
340	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 315-324.	0.4	2
343	Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis. <i>Cancer Research</i> , 2022, 82, 2552-2564.	0.4	6
344	Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 450-455.	0.2	11
345	Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. <i>Lung Cancer</i> , 2022, 169, 102-114.	0.9	8
346	A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. <i>Cancer Science</i> , 0, , .	1.7	4
348	Locoregionally Advanced, BRAF V600L-Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of BRAF and MEK Inhibitors. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
349	Novel GLCC11-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis. <i>European Journal of Endocrinology</i> , 2022, 187, 185-196.	1.9	1
350	Three cases of malignant melanoma with rhabdomyolysis during combination therapy of dabrafenib and trametinib. <i>Skin Cancer</i> , 2022, 37, 16-21.	0.1	0
351	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
352	COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 4178-4188.	0.8	57
353	Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. <i>Cancers</i> , 2022, 14, 3587.	1.7	6
354	What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?. <i>Journal of Clinical Oncology</i> , 2022, 40, 4161-4165.	0.8	6

#	ARTICLE	IF	CITATIONS
355	Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	1
356	State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain. <i>Neurosurgical Review</i> , 2022, 45, 3119-3138.	1.2	1
357	Targeting Melanin in Melanoma with Radionuclide Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9520.	1.8	5
358	Apigenin Induced Apoptosis by Downregulating Sulfiredoxin Expression in Cutaneous Squamous Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-14.	1.9	4
359	Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	5
360	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 554-572.	1.5	3
361	Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
362	Vulvovaginal melanoma. , 2023, , 279-304.		0
363	Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 110, 102463.	3.4	10
364	Conquering oncogenic KRAS and its bypass mechanisms. <i>Theranostics</i> , 2022, 12, 5691-5709.	4.6	1
365	Substanzen gegen molekulare Zielstrukturen. <i>Springer Reference Medizin</i> , 2022, , 1-14.	0.0	0
366	Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial – ECOG-ACRIN EA6134. <i>Journal of Clinical Oncology</i> , 2023, 41, 186-197.	0.8	140
367	Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?. <i>Biomedicines</i> , 2022, 10, 2424.	1.4	4
368	Novel Therapies in Clinical Development for Advanced Disease. , 0, , .		0
371	Targeted Therapy and Immunotherapy in Melanoma. <i>Dermatologic Clinics</i> , 2023, 41, 65-77.	1.0	14
372	Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. <i>Journal of Personalized Medicine</i> , 2022, 12, 1746.	1.1	5
373	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
374	Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma. <i>Cancers</i> , 2022, 14, 4930.	1.7	7

#	ARTICLE	IF	CITATIONS
377	Clinical associations and genetic interactions of oncogenic BRAF alleles. PeerJ, 0, 10, e14126.	0.9	0
378	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. , 2022, 240, 108301.		9
379	Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer. European Journal of Pharmaceutical Sciences, 2023, 180, 106311.	1.9	2
380	Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study. International Journal of Clinical Oncology, 2023, 28, 139-144.	1.0	2
381	Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis. Advances in Protein Chemistry and Structural Biology, 2023, , 179-201.	1.0	4
382	High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer. Molecular Cancer Therapeutics, 2023, 22, 227-239.	1.9	3
383	Targeted Therapy for Melanomas Without BRAF V600 Mutation. Current Oncology Reports, 2022, 24, 1873-1881.	1.8	3
384	Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial. BMJ Open, 2022, 12, e063700.	0.8	0
385	Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncology Letters, 2022, 25, .	0.8	9
386	BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers, 2023, 15, 141.	1.7	14
387	Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers, 2023, 15, 31.	1.7	1
388	Discovery of Novel 1,2,4-Oxadiazolyl Triazole Hybrids as Raf Inhibitors for the Treatment of Melanoma. ChemistrySelect, 2022, 7, .	0.7	1
389	Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. JAMA Network Open, 2022, 5, e2245269.	2.8	19
390	Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy. Acta Oncologica, 2023, 62, 62-69.	0.8	5
391	PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	8
392	Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma. Journal of the European Academy of Dermatology and Venereology, 2023, 37, .	1.3	0
393	Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. BMC Health Services Research, 2023, 23, .	0.9	3
394	Phytochemical Constituents and Derivatives of Cannabis sativa; Bridging the Gap in Melanoma Treatment. International Journal of Molecular Sciences, 2023, 24, 859.	1.8	8

#	ARTICLE	IF	CITATIONS
395	Severe colitis in patients with melanoma treated with <scp>BRAF</scp>/<scp>MEK</scp> inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 792-799.	1.9	3
396	Surgical treatment options in a patient with borderline resectable tumour â€“ a case report of a 54-year-old patient with locally advanced melanoma. <i>Postepy Dermatologii I Alergologii</i> , 2023, 40, 178-180.	0.4	0
397	Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. <i>ESMO Open</i> , 2023, 8, 100788.	2.0	22
398	Nebenwirkungen und deren Management. , 2022, , 121-146.		0
399	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
400	Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines. <i>Translational Medicine Communications</i> , 2023, 8, .	0.5	2
401	Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study. <i>Cancers</i> , 2023, 15, 1426.	1.7	0
402	Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene. <i>Melanoma Research</i> , 2023, 33, 247-251.	0.6	3
403	Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets. <i>Translational Lung Cancer Research</i> , 2023, 12, 707-718.	1.3	2
405	How have immune checkpoint inhibitors transformed melanoma treatment?. <i>Trends in Urology & Men's Health</i> , 2023, 14, 26-30.	0.2	0
406	Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. <i>Cancer Research Communications</i> , 2023, 3, 821-829.	0.7	9
407	Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. , 2023, 11, e005828.		3
408	Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An <i>In Vivo</i>â€“<i>In Vitro</i>â€“<i>In Silico</i> Approach. <i>Molecular Pharmaceutics</i> , 0, , .	2.3	6
409	N-acetylcysteine overcomes NF1 loss-driven resistance to PI3KÎ± inhibition in breast cancer. <i>Cell Reports Medicine</i> , 2023, 4, 101002.	3.3	3
410	Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. <i>Clinical Cancer Research</i> , 2023, 29, 2753-2760.	3.2	19
411	Targeted therapy. , 2023, , 205-411.		0
447	Targeted Treatments for Cutaneous Melanoma. , 2023, , 1787-1800.		0
452	Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1

#	ARTICLE	IF	CITATIONS
460	Modelling adaptive therapy for tumor using reaction-diffusion equation. AIP Conference Proceedings, 2024, , .	0.3	0
466	Tumoren der Haut. , 2024, , 945-962.		0